Legend Biotech Corporation (FRA:9LB)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.54B -36.8% |
| Revenue (ttm) | 1.11B +59.5% |
| Net Income | -80.09M |
| EPS | -0.44 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 33.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 18.00 |
| Previous Close | 18.40 |
| Day's Range | 17.70 - 18.00 |
| 52-Week Range | 13.80 - 31.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About Legend Biotech
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lym... [Read more]
Financial Performance
In 2025, Legend Biotech's revenue was $1.03 billion, an increase of 64.02% compared to the previous year's $627.30 million. Losses were -$296.80 million, 67.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Legend Biotech price target lowered to $24 from $29 at TD Cowen
TD Cowen lowered the firm’s price target on Legend Biotech (LEGN) to $24 from $29 and keeps a Hold rating on the shares. Carvykti posted a solid Q2 with global…
Legend Biotech price target lowered to $78 from $80 at Barclays
Barclays lowered the firm’s price target on Legend Biotech (LEGN) to $78 from $80 and keeps an Overweight rating on the shares post the Q2 report. Increased uptake in the…
Legend Biotech downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Legend Biotech (LEGN) to Perform from Outperform.
Oppenheimer downgrades Legend Biotech to Perform on CEO/competition overhangs
As previously reported, Oppenheimer downgraded Legend Biotech (LEGN) to Perform from Outperform with a $40 price target. Following in vivo CART readout back on June 2, Legend significantly underperfor...
Legend Biotech price target raised to $49 from $48 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Legend Biotech (LEGN) to $49 from $48 and keeps an Overweight rating on the shares.
Legend Biotech Earnings Call Transcript: Q2 2026
Achieved first quarter of company-wide profitability, driven by 50% year-over-year CARVYKTI sales growth and improved operating leverage. Strong cash position and a successful equity raise support continued pipeline advancement, with ongoing expansion into earlier lines and new markets.
Legend Biotech Earnings release: Q2 2026
Legend Biotech released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Legend Biotech Slides: Q2 2026
Legend Biotech has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
Legend Biotech reports Q2 EPS 16c vs. 3c last year
Reports Q2 revenue $387.5M, consensus $351.75M. “Our second quarter results demonstrate the strength of our commercial and innovation engines at Legend Biotech (LEGN),” said Alan Bash, Interim Chief E...
Legend Biotech falls -15.1%
Legend Biotech (LEGN) is down -15.1%, or -$3.35 to $18.87.
Legend Biotech falls -12.5%
Legend Biotech (LEGN) is down -12.5%, or -$2.77 to $19.45.
Legend Biotech price target lowered to $59 from $63 at RBC Capital
RBC Capital lowered the firm’s price target on Legend Biotech (LEGN) to $59 from $63 but keeps an Outperform rating on the shares. Despite a small sample and limited follow-up,…
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim CEO
Legend Biotech (LEGN) announced that Ying Huang, Ph.D., has stepped down as CEO and as a member of the Board of Directors, effective as of July 24. Dr. Huang will…
Legend Biotech Announces CEO Transition
BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that Ying Huang, Ph...
Legend Biotech downgraded to Neutral from Buy at UBS
UBS downgraded Legend Biotech (LEGN) to Neutral from Buy with a price target of $28, down from $49. The firm sees a smaller opportunity for Carvykti due to intensifying competition…
Legend Biotech resumed with a Neutral at JPMorgan
JPMorgan resumed coverage of Legend Biotech (LEGN) with a Neutral rating and $35 price target While Carvykti has had a “healthy launch,” JPMorgan struggles to see what near-term event might…
Legend Biotech price target lowered to $63 from $64 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Legend Biotech (LEGN) to $63 from $64 and keeps an Outperform rating on the shares as part of a…
Legend Biotech falls -14.4%
Legend Biotech (LEGN) is down -14.4%, or -$4.82 to $28.70.
Legend Biotech falls -12.2%
Legend Biotech (LEGN) is down -12.2%, or -$4.09 to $29.43.
Legend Biotech 7.7M share Spot Secondary priced at $29.35
Morgan Stanley, Jefferies, Citi and Deutsche Bank are acting as joint book running managers for the offering. The deal priced below last closing price of $33.52.
Legend Biotech Corporation Announces Pricing of Public Offering
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an u...
Legend Biotech secondary offering; price range $29.35-$31.35
Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are serving as joint book-running managers for the offering.
Legend Biotech announces $225M offering of American Depositary Shares
Legend Biotech (LEGN) announced that it has commenced an underwritten public offering of $225M of American Depositary Shares, each representing two ordinary shares of the company. All of the ADSs…
Legend Biotech Corporation Announces Proposed Public Offering
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that it has commenc...
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependen...